Significantly different indicators, including T-bil (total bilirubin) (p=0.025), the percentage of CD3+γδT+Vδ2+TIM-3+ T cells (P=0.050), the percentage of CD3+γδT+CD28- T cells (p=0.039), and clinically relevant indicators such as age, gender, smoking history, tumor type, TPS (PD-L1), and the percentage of CD3+PD-1+ T cells, were selected as candidate indicators for model development. This evidence concerns the gene CD28 and neoplasm.